Srikanth Reddy Boddu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Srikanth Reddy Boddu has a total of 221 co-authors. Here are the top co-authors by number of shared publications:
- Adnan H. Siddiqui
Department of Neurosurgery, State University of New York at Buffalo, Buffalo, New York, USA
4 shared publications - Jared Knopman
Department of Neurological Surgery, Weill Cornell Medicine/New York-Presbyterian Hospital, New York, United States
4 shared publications - Joseph Anthony Carnevale
Department of Neurological Surgery, Weill Cornell Medicine/New York-Presbyterian Hospital, New York, United States
4 shared publications Marc Dinkin
Departments of Neurology and Ophthalmology, NewYork-Presbyterian Hospital, Weill Cornell Medical College, New York, New York, USA
4 shared publicationsY Pierre Gobin
Department of Neurological Surgery, New York Presbyterian Hospital/Weill Cornell Medical College, New York, New York, USA
4 shared publications- Adam Andrew Dmytriw
Nuffield Department of Surgical Sciences, Medical Sciences Division, University of Oxford, Oxford, United Kingdom
3 shared publications
Latest Publications
- 2 November 2026
- Published by Wolters Kluwer Health in Neurosurgery
The Contour Neurovascular System Versus Woven Endobridge for Endovascular Embolization of Cerebral Aneurysms: A Propensity Score-matched Cohort Study
BACKGROUND AND OBJECTIVES: The Woven Endobridge (WEB) and the Contour Neurovascular System (Contour) are both intrasaccular devices used to treat cerebral aneurysms. We compared outcomes of these 2 devices using data from 2 large registries. METHODS: Data were sourced from the WorldWideWEB Consortium, which included 1363 cases treated with WEB from 2017, and a registry of 277 Contour cases from 10 European centers starting the same year. Patient demographics, aneurysm characteristics, procedural specifics, and outcomes were analyzed. Propensity score matching was applied for comparison. RESULTS: Before matching, the Contour group had more men (37.9% vs 30.8%), more asymptomatic cases (83.4% vs 70.3%), and fewer acute subarachnoid hemorrhage cases (10.8% vs 26.2%). After matching, no significant differences were found in demographics or aneurysm characteristics between groups. The median age was 60 years, and median aneurysm dimensions were comparable. Logistic regression showed no significant differences between WEB and Contour in achieving complete occlusion (odds ratio [OR] = 1.01, 95% CI, 0.67-1.52, P = .971), adequate occlusion (OR = 0.85, 95% CI, 0.41-1.76, P = .665), or achieving modified Rankin Scale 0 to 2 at last follow-up (OR = 0.48, 95% CI, 0.21-1.02, P = .064). Retreatment (OR = 2.23, P = .086), thromboembolic complications (OR = 0.75, P = .452), and adjunctive treatment use (OR = 1.93, P = .141) were also similar. CONCLUSION: The WEB and Contour demonstrated comparable clinical and angiographic outcomes in this large multicenter study comprised majority small, asymptomatic cerebral aneurysms.
- 2 November 2026
- Published by Wolters Kluwer Health in Neurosurgery
The Contour Neurovascular System Versus Woven Endobridge for Endovascular Embolization of Cerebral Aneurysms: A Propensity Score-matched Cohort Study
BACKGROUND AND OBJECTIVES: The Woven Endobridge (WEB) and the Contour Neurovascular System (Contour) are both intrasaccular devices used to treat cerebral aneurysms. We compared outcomes of these 2 devices using data from 2 large registries. METHODS: Data were sourced from the WorldWideWEB Consortium, which included 1363 cases treated with WEB from 2017, and a registry of 277 Contour cases from 10 European centers starting the same year. Patient demographics, aneurysm characteristics, procedural specifics, and outcomes were analyzed. Propensity score matching was applied for comparison. RESULTS: Before matching, the Contour group had more men (37.9% vs 30.8%), more asymptomatic cases (83.4% vs 70.3%), and fewer acute subarachnoid hemorrhage cases (10.8% vs 26.2%). After matching, no significant differences were found in demographics or aneurysm characteristics between groups. The median age was 60 years, and median aneurysm dimensions were comparable. Logistic regression showed no significant differences between WEB and Contour in achieving complete occlusion (odds ratio [OR] = 1.01, 95% CI, 0.67-1.52, P = .971), adequate occlusion (OR = 0.85, 95% CI, 0.41-1.76, P = .665), or achieving modified Rankin Scale 0 to 2 at last follow-up (OR = 0.48, 95% CI, 0.21-1.02, P = .064). Retreatment (OR = 2.23, P = .086), thromboembolic complications (OR = 0.75, P = .452), and adjunctive treatment use (OR = 1.93, P = .141) were also similar. CONCLUSION: The WEB and Contour demonstrated comparable clinical and angiographic outcomes in this large multicenter study comprised majority small, asymptomatic cerebral aneurysms.
- 1 August 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (5) , 1414-1420
Catheterization techniques and outcomes of transvenous embolization of cerebrospinal fluid–venous fistulas in the management of spontaneous intracranial hypotension: case series
Background Endovascular transvenous embolization of spinal cerebrospinal fluid–venous fistulas (CVFs) has been shown in small studies to be a safe and effective treatment for spontaneous intracranial hypotension (SIH). Objective To validate the safety and effectiveness of this procedure and to describe catheterization techniques available to safely perform these embolization procedures. Results A total of 21 patients with confirmed CVF underwent 23 endovascular embolization procedures; 18 (86%) patients achieved both clinical and radiographic resolution of their SIH. There were no major neurologic complications from any procedure. One patient had postoperative pulmonary embolism and deep vein thrombosis. The most common side effects were prolonged symptoms of rebound intracranial hypertension (29%) and prolonged back pain with radiculopathy (24%). The azygous vein was used for catheterizing the level of interest in 83% of embolization procedures; the lumbar ascending vein was used for catheterization in 17% of the procedures; and direct catheterization of the segmental/foraminal vein at the level of interest was performed in 61% of the procedures. The epidural venous plexus was accessed and traversed to the level of interest in 39% of the procedures. Conclusion Endovascular transvenous embolization of CVF is a safe, well-tolerated, and effective treatment for SIH. Given the variability of the venous anatomy, there are multiple routes of catheterization that can be performed to access the level of interest when performing these procedures.
- 1 August 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (5) , 1414-1420
Catheterization techniques and outcomes of transvenous embolization of cerebrospinal fluid–venous fistulas in the management of spontaneous intracranial hypotension: case series
Background Endovascular transvenous embolization of spinal cerebrospinal fluid–venous fistulas (CVFs) has been shown in small studies to be a safe and effective treatment for spontaneous intracranial hypotension (SIH). Objective To validate the safety and effectiveness of this procedure and to describe catheterization techniques available to safely perform these embolization procedures. Results A total of 21 patients with confirmed CVF underwent 23 endovascular embolization procedures; 18 (86%) patients achieved both clinical and radiographic resolution of their SIH. There were no major neurologic complications from any procedure. One patient had postoperative pulmonary embolism and deep vein thrombosis. The most common side effects were prolonged symptoms of rebound intracranial hypertension (29%) and prolonged back pain with radiculopathy (24%). The azygous vein was used for catheterizing the level of interest in 83% of embolization procedures; the lumbar ascending vein was used for catheterization in 17% of the procedures; and direct catheterization of the segmental/foraminal vein at the level of interest was performed in 61% of the procedures. The epidural venous plexus was accessed and traversed to the level of interest in 39% of the procedures. Conclusion Endovascular transvenous embolization of CVF is a safe, well-tolerated, and effective treatment for SIH. Given the variability of the venous anatomy, there are multiple routes of catheterization that can be performed to access the level of interest when performing these procedures.
- 19 February 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (1) , 11-19
The River study: the first prospective multicenter trial of a novel venous sinus stent for the treatment of idiopathic intracranial hypertension
Background The River stent is the first stent specifically designed for intracranial venous sinuses. We report the 1-year results of the River trial, performed to obtain Humanitarian Device Exemption approval of the River stent in the United States (US). Methods The River trial was a prospective, open-label, multicenter, single-arm trial which enrolled 39 subjects at 5 US centers. Eligible patients had clinical diagnosis of idiopathic intracranial hypertension (IIH) with severe headaches or visual field loss and had failed medical therapy. The primary safety endpoint was the 1-year rate of major adverse events compared with cerebrospinal fluid (CSF) shunting using historical controls. The primary benefit endpoint was a composite at 1 year of clinical improvement and absence of venous sinus stenosis. Secondary endpoints included improvement in pulsatile tinnitus, visual symptoms, quality of life (QOL) scores, and medications. Results All procedures were technically successful. There was one serious adverse event, a gastrointestinal hemorrhage observed 2 months after the procedure while the patient was still on dual antiplatelet therapy. The primary safety endpoint was met with a rate of major adverse event of 5.4% versus 51.7% for CSF shunts. The primary benefit endpoint was achieved in 60% of trial participants. Additional improvements were also observed in opening CSF pressure, headaches, papilledema, pulsatile tinnitus, visual symptoms, and QOL scores. Post hoc analysis demonstrated that subjects with minimal or absent papilledema at baseline showed similar improvement compared with subjects with papilledema at baseline, in terms of headaches, pulsatile tinnitus, and QOL. Conclusions The River study 1- year results establish safety and suggest efficacy for venous sinus stenting in IIH subjects who have failed medical therapy.
- 19 February 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (1) , 11-19
The River study: the first prospective multicenter trial of a novel venous sinus stent for the treatment of idiopathic intracranial hypertension
Background The River stent is the first stent specifically designed for intracranial venous sinuses. We report the 1-year results of the River trial, performed to obtain Humanitarian Device Exemption approval of the River stent in the United States (US). Methods The River trial was a prospective, open-label, multicenter, single-arm trial which enrolled 39 subjects at 5 US centers. Eligible patients had clinical diagnosis of idiopathic intracranial hypertension (IIH) with severe headaches or visual field loss and had failed medical therapy. The primary safety endpoint was the 1-year rate of major adverse events compared with cerebrospinal fluid (CSF) shunting using historical controls. The primary benefit endpoint was a composite at 1 year of clinical improvement and absence of venous sinus stenosis. Secondary endpoints included improvement in pulsatile tinnitus, visual symptoms, quality of life (QOL) scores, and medications. Results All procedures were technically successful. There was one serious adverse event, a gastrointestinal hemorrhage observed 2 months after the procedure while the patient was still on dual antiplatelet therapy. The primary safety endpoint was met with a rate of major adverse event of 5.4% versus 51.7% for CSF shunts. The primary benefit endpoint was achieved in 60% of trial participants. Additional improvements were also observed in opening CSF pressure, headaches, papilledema, pulsatile tinnitus, visual symptoms, and QOL scores. Post hoc analysis demonstrated that subjects with minimal or absent papilledema at baseline showed similar improvement compared with subjects with papilledema at baseline, in terms of headaches, pulsatile tinnitus, and QOL. Conclusions The River study 1- year results establish safety and suggest efficacy for venous sinus stenting in IIH subjects who have failed medical therapy.
- 4 April 2024
- Published by Elsevier in World Neurosurgery
- Vol. 184, 361-371
Foundations of the Diagnosis and Management of Idiopathic Intracranial Hypertension and Pulsatile Tinnitus
- 4 April 2024
- Published by Elsevier in World Neurosurgery
- Vol. 184, 361-371
Foundations of the Diagnosis and Management of Idiopathic Intracranial Hypertension and Pulsatile Tinnitus
- 4 April 2024
- Published by Elsevier in World Neurosurgery
- Vol. 184, 372-386
Challenges in the use of Venous Sinus Stenting in the Treatment of Idiopathic Intracranial Hypertension and Pulsatile Tinnitus
- 4 April 2024
- Published by Elsevier in World Neurosurgery
- Vol. 184, 372-386
Challenges in the use of Venous Sinus Stenting in the Treatment of Idiopathic Intracranial Hypertension and Pulsatile Tinnitus
- 4 April 2024
- Published by Elsevier in World Neurosurgery
- Vol. 184, 387-394
Future Directions and Innovations in Venous Sinus Stenting
- 4 April 2024
- Published by Elsevier in World Neurosurgery
- Vol. 184, 387-394
Future Directions and Innovations in Venous Sinus Stenting
- Open Access
- 30 July 2023
- Published by BMJ
- Vol. 15 (Suppl 1) , A65-A66
P-015 Middle Meningeal artery embolization: complete institutional report of 294 non-acute subdural hematomas with outcomes and risk factors for recurrence
Introduction/Purpose Non-Acute Subdural Hematoma (NASDH) is challenging to treat due to high recurrence rates ranging from 2-37%. Middle meningeal artery embolization (MMAe) is a minimally invasive procedure which improve outcomes in NASDH. This study evaluates clinical and radiographic characteristics of patients with NASDH undergoing MMAe when utilized upfront, prophylactically, or as a salvage modality after surgical evacuation. Methods This prospective study followed patients undergoing MMAe for NASDH from 2016-2022. All patients were diagnosed with a NASDH on CT imaging and underwent MMAe by the lead Neurointerventionalist. Outcomes were assessed based on radiographic and clinical follow up within one-year follow-up. Primary outcome of NASDH recurrence following MMAe was defined as hematoma recurrence requiring surgical evacuation, repeat MMAe, or both within the one-year. Radiographic outcomes included SDH recurrence, reduction of hematoma width and midline shift, and collection density evaluation (mean Hounsfield Units) up to the longest follow-up. Subgroup analyses stratified outcomes by MMAe indication: upfront, salvage, or prophylactic. Oncologic, coagulopathic, and anticoagulant-antiplatelet (ACAP) patients were also assessed. Post-MMAe clinical outcomes were assessed by modified Rankin scale (mRS). Results 236 NASDH patients underwent 294 MMAe. 115 (48.7%), 92 (39.0%), and 29 (12.3%) patients received upfront (previously untreated and nonoperative NASDH), prophylactic (MMAe following hematoma evacuation), and salvage (individuals with NASDH recurrence following a previous surgical evacuation) MMAe, respectively. Upfront MMAe was performed more frequently than prophylactic and salvage for patients with co-existing malignancy (29.6%, 12.0%, 20.7%; p < 0.01) and coagulopathy (17.4%, 4.3%, 10.3%; p = 0.01). Polyvinyl alcohol was preferred over onyx as embolic agent (94.1% vs 5.9%; p < 0.01). There were 16 (5.4%) recurrences after MMAe, of which 5 (1.7%) received a craniotomy, 7 (2.4%) received an MMA embolization, and 4 (1.3%) underwent both MMAe and surgical evacuation. Clinical outcomes did not differ between MMAe indications at longest follow-up. Statistically significant decreases in collection size and density were seen across all cohorts on follow-up. Subgroup analysis revealed decreased NASDH recurrence in oncologic, coagulopathic, and ACAP patients. Multivariate regression identified history of falls, coagulopathy, hematoma size, and male sex increased the likelihood of NASDH recurrence requiring repeat intervention following MMAe (p < 0.05); whereas, periprocedural SEPS and presence of subdural septation/membranes decreased the likelihood of recurrence requiring intervention (p < 0.05). Hematoma size of 4.63 mm or greater on initial presentation were 2.21 times more likely to recur and patients with cancer were 3 times more likely to have subdural hematoma recurrence. Conclusions MMAe is a viable treatment for reducing recurrence and improving outcomes in patients with NASDH compared to historical controls and prevent the need for the first time or repeat surgical evacuation., noting beneficial radiographic and clinical outcomes when performed upfront, prophylactically, or as salvage treatment. This data reports one of the largest analyses of patients having undergone MMAe with clinical follow-up alongside measurements of collection sizes and density values before and after embolization. MMAe in high-risk coagulopathic, oncologic, and anticoagulated patients can reduce collection recurrence in special populations predisposed to increased hematoma formation and recurrence. Disclosures J. Carnevale: None. S. Guadix: None. M. Wood: None. S. Sundararajan: None. N. Kharas: None. J. Goldberg: None. A. Ramos: None. J. Schwarz: None. S. Boddu: None. J. Knopman: None.
- 30 July 2023
- Published by BMJ
- Vol. 15 (Suppl 1) , A65-A66
Open AccessP-015 Middle Meningeal artery embolization: complete institutional report of 294 non-acute subdural hematomas with outcomes and risk factors for recurrence
Introduction/Purpose Non-Acute Subdural Hematoma (NASDH) is challenging to treat due to high recurrence rates ranging from 2-37%. Middle meningeal artery embolization (MMAe) is a minimally invasive procedure which improve outcomes in NASDH. This study evaluates clinical and radiographic characteristics of patients with NASDH undergoing MMAe when utilized upfront, prophylactically, or as a salvage modality after surgical evacuation. Methods This prospective study followed patients undergoing MMAe for NASDH from 2016-2022. All patients were diagnosed with a NASDH on CT imaging and underwent MMAe by the lead Neurointerventionalist. Outcomes were assessed based on radiographic and clinical follow up within one-year follow-up. Primary outcome of NASDH recurrence following MMAe was defined as hematoma recurrence requiring surgical evacuation, repeat MMAe, or both within the one-year. Radiographic outcomes included SDH recurrence, reduction of hematoma width and midline shift, and collection density evaluation (mean Hounsfield Units) up to the longest follow-up. Subgroup analyses stratified outcomes by MMAe indication: upfront, salvage, or prophylactic. Oncologic, coagulopathic, and anticoagulant-antiplatelet (ACAP) patients were also assessed. Post-MMAe clinical outcomes were assessed by modified Rankin scale (mRS). Results 236 NASDH patients underwent 294 MMAe. 115 (48.7%), 92 (39.0%), and 29 (12.3%) patients received upfront (previously untreated and nonoperative NASDH), prophylactic (MMAe following hematoma evacuation), and salvage (individuals with NASDH recurrence following a previous surgical evacuation) MMAe, respectively. Upfront MMAe was performed more frequently than prophylactic and salvage for patients with co-existing malignancy (29.6%, 12.0%, 20.7%; p < 0.01) and coagulopathy (17.4%, 4.3%, 10.3%; p = 0.01). Polyvinyl alcohol was preferred over onyx as embolic agent (94.1% vs 5.9%; p < 0.01). There were 16 (5.4%) recurrences after MMAe, of which 5 (1.7%) received a craniotomy, 7 (2.4%) received an MMA embolization, and 4 (1.3%) underwent both MMAe and surgical evacuation. Clinical outcomes did not differ between MMAe indications at longest follow-up. Statistically significant decreases in collection size and density were seen across all cohorts on follow-up. Subgroup analysis revealed decreased NASDH recurrence in oncologic, coagulopathic, and ACAP patients. Multivariate regression identified history of falls, coagulopathy, hematoma size, and male sex increased the likelihood of NASDH recurrence requiring repeat intervention following MMAe (p < 0.05); whereas, periprocedural SEPS and presence of subdural septation/membranes decreased the likelihood of recurrence requiring intervention (p < 0.05). Hematoma size of 4.63 mm or greater on initial presentation were 2.21 times more likely to recur and patients with cancer were 3 times more likely to have subdural hematoma recurrence. Conclusions MMAe is a viable treatment for reducing recurrence and improving outcomes in patients with NASDH compared to historical controls and prevent the need for the first time or repeat surgical evacuation., noting beneficial radiographic and clinical outcomes when performed upfront, prophylactically, or as salvage treatment. This data reports one of the largest analyses of patients having undergone MMAe with clinical follow-up alongside measurements of collection sizes and density values before and after embolization. MMAe in high-risk coagulopathic, oncologic, and anticoagulated patients can reduce collection recurrence in special populations predisposed to increased hematoma formation and recurrence. Disclosures J. Carnevale: None. S. Guadix: None. M. Wood: None. S. Sundararajan: None. N. Kharas: None. J. Goldberg: None. A. Ramos: None. J. Schwarz: None. S. Boddu: None. J. Knopman: None.
- 11 May 2023
- Published by Springer Nature in Translational Stroke Research
- Vol. 15 (3) , 591-598
Long-Term Follow-Up of Cerebral Aneurysms Completely Occluded at 6 Months After Intervention with the Woven EndoBridge (WEB) Device: a Retrospective Multicenter Observational Study
The Woven EndoBridge (WEB) device has been widely used to treat intracranial wide neck bifurcation aneurysms. Initial studies have demonstrated that approximately 90% of patients have same or improved long-term aneurysm occlusion after the initial 6-month follow up. The aim of this study is to assess the long-term follow-up in aneurysms that have achieved complete occlusion at 6 months. We also compared the predictive value of different imaging modalities used. This is an analysis of a prospectively maintained database across 13 academic institutions. We included patients with previously untreated cerebral aneurysms embolized using the WEB device who achieved complete occlusion at first follow-up and had available long-term follow-up. A total of 95 patients with a mean age of 61.6 ± 11.9 years were studied. The mean neck diameter and height were 3.9 ± 1.3 mm and 6.0 ± 1.8 mm, respectively. The mean time to first and last follow-up was 5.4 ± 1.8 and 14.1 ± 12.9 months, respectively. Out of all the aneurysms that were completely occluded at 6 months, 84 (90.3%) showed complete occlusion at the final follow-up, and 11(11.5%) patients did not achieve complete occlusion. The positive predictive value (PPV) of complete occlusion at first follow was 88.4%. Importantly, this did not differ between digital subtraction angiography (DSA), magnetic resonance angiography (MRA), or computed tomography angiography (CTA). This study underlines the importance of repeat imaging in patients treated with the WEB device even if complete occlusion is achieved short term. Follow-up can be performed using DSA, MRA or CTA with no difference in positive predictive value.
- 11 May 2023
- Published by Springer Nature in Translational Stroke Research
- Vol. 15 (3) , 591-598
Long-Term Follow-Up of Cerebral Aneurysms Completely Occluded at 6 Months After Intervention with the Woven EndoBridge (WEB) Device: a Retrospective Multicenter Observational Study
The Woven EndoBridge (WEB) device has been widely used to treat intracranial wide neck bifurcation aneurysms. Initial studies have demonstrated that approximately 90% of patients have same or improved long-term aneurysm occlusion after the initial 6-month follow up. The aim of this study is to assess the long-term follow-up in aneurysms that have achieved complete occlusion at 6 months. We also compared the predictive value of different imaging modalities used. This is an analysis of a prospectively maintained database across 13 academic institutions. We included patients with previously untreated cerebral aneurysms embolized using the WEB device who achieved complete occlusion at first follow-up and had available long-term follow-up. A total of 95 patients with a mean age of 61.6 ± 11.9 years were studied. The mean neck diameter and height were 3.9 ± 1.3 mm and 6.0 ± 1.8 mm, respectively. The mean time to first and last follow-up was 5.4 ± 1.8 and 14.1 ± 12.9 months, respectively. Out of all the aneurysms that were completely occluded at 6 months, 84 (90.3%) showed complete occlusion at the final follow-up, and 11(11.5%) patients did not achieve complete occlusion. The positive predictive value (PPV) of complete occlusion at first follow was 88.4%. Importantly, this did not differ between digital subtraction angiography (DSA), magnetic resonance angiography (MRA), or computed tomography angiography (CTA). This study underlines the importance of repeat imaging in patients treated with the WEB device even if complete occlusion is achieved short term. Follow-up can be performed using DSA, MRA or CTA with no difference in positive predictive value.
- 6 September 2022
- Published by Springer Nature in Translational Stroke Research
- Vol. 14 (4) , 455-464
The Woven EndoBridge (WEB) Device for the Treatment of Intracranial Aneurysms: Ten Years of Lessons Learned and Adjustments in Practice from the WorldWideWEB Consortium
Several studies have shown promising outcomes of the Woven EndoBridge (WEB) device for the treatment of wide-necked intracranial bifurcation aneurysms. This is a multicenter study attempts to explore the changes in trends and treatment outcomes over time for WEB embolization of intracranial aneurysms. The WorldWideWEB consortium is a retrospective multicenter collaboration of data from international centers spanning from January 2011 and June 2021, with no limitations on aneurysm location or rupture status. Both bifurcation and sidewall aneurysms were included. These patients were stratified based on treatment year into five treatment intervals: 2011–2015 (N = 66), 2016–2017 (N = 77), 2018 (N = 66), 2019 (N = 300), and 2020–2021 (N = 173). Patient characteristics and angiographic and clinical outcomes were compared between these time intervals. This study comprised 671 patients (median age 61.4 years; 71.2% female) with 682 intracranial aneurysms. Over time, we observed an increasing tendency to treat patients presenting with ruptured aneurysms and aneurysms with smaller neck, diameter, and dome widths. Furthermore, we observed a trend towards more off-label use of the WEB for sidewall aneurysms and increased adoption of transradial access for WEB deployment. Moreover, the proportion of patients with adequate WEB occlusion immediately and at last follow-up was significantly higher in more recent year cohorts, as well as lower rates of compaction and retreatment. Mortality and complications did not differ over time. This learning curve study suggests improved experience using the WEB for the treatment of intracranial aneurysms and has yielded higher rates of adequate occlusion over time.
- 6 September 2022
- Published by Springer Nature in Translational Stroke Research
- Vol. 14 (4) , 455-464
The Woven EndoBridge (WEB) Device for the Treatment of Intracranial Aneurysms: Ten Years of Lessons Learned and Adjustments in Practice from the WorldWideWEB Consortium
Several studies have shown promising outcomes of the Woven EndoBridge (WEB) device for the treatment of wide-necked intracranial bifurcation aneurysms. This is a multicenter study attempts to explore the changes in trends and treatment outcomes over time for WEB embolization of intracranial aneurysms. The WorldWideWEB consortium is a retrospective multicenter collaboration of data from international centers spanning from January 2011 and June 2021, with no limitations on aneurysm location or rupture status. Both bifurcation and sidewall aneurysms were included. These patients were stratified based on treatment year into five treatment intervals: 2011–2015 (N = 66), 2016–2017 (N = 77), 2018 (N = 66), 2019 (N = 300), and 2020–2021 (N = 173). Patient characteristics and angiographic and clinical outcomes were compared between these time intervals. This study comprised 671 patients (median age 61.4 years; 71.2% female) with 682 intracranial aneurysms. Over time, we observed an increasing tendency to treat patients presenting with ruptured aneurysms and aneurysms with smaller neck, diameter, and dome widths. Furthermore, we observed a trend towards more off-label use of the WEB for sidewall aneurysms and increased adoption of transradial access for WEB deployment. Moreover, the proportion of patients with adequate WEB occlusion immediately and at last follow-up was significantly higher in more recent year cohorts, as well as lower rates of compaction and retreatment. Mortality and complications did not differ over time. This learning curve study suggests improved experience using the WEB for the treatment of intracranial aneurysms and has yielded higher rates of adequate occlusion over time.
- 15 September 2018
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 11 (3) , 300-306
Impaired drainage of vein of Labbé following venous sinus stenting for idiopathic intracranial hypertension
Purpose: The impact of venous sinus stenting (VSS) on vein of Labbé (VOL) drainage is poorly understood. The purpose of the study is to examine the incidence and potential high risk factors of impaired VOL drainage among idiopathic intracranial hypertension (IIH) patients following VSS.Materials and methods: Institutional review board approved prospective evaluation of all IIH patients who underwent VSS over a 5 year period (January 2012 to December 2017) at Weill Cornell Medical Center constituted the study population. Patient demographics, procedural details (laterality of stenting, balloon angioplasty, number of stents, and stent diameters), morphology of the VOL and changes in the flow in the VOL, type of sinus stenosis, and transverse sinus symmetry were evaluated. We used χ2analysis to evaluate impaired VOL drainage against other variables. Statistical significance was set at 0.05.Results: 70 consecutive patients (67 women, 3 men) with a mean age of 31±9.8 years underwent VSS. Stenosis was extrinsic in 63% (n=44) and intrinsic in 37% (n=26) of patients. Impaired drainage of the VOL was detected in 9/70 (13%) patients. Ipsilateral VOL was recognized as dominant in 20% (n=14), co-dominant in 51% (n=36), and non-dominant in 29% (n=20) of patients. Impaired VOL drainage was significantly associated with ipsilateral VOL dominance (P=0.001) and stent diameter of ≥9 mm (P=0.042). All patients demonstrated widely patent VOL on follow-up contrast enhanced MR venography at 3 months and 24 months.Conclusion: Impaired drainage of the ipsilateral VOL is a potential consequence of VSS with 13% incidence, and has significant association with ipsilateral superficial cortical venous drainage via dominant VOL and stent diameter of ≥9 mm.Clinical trial registration: NCT01407809.
- 15 September 2018
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 11 (3) , 300-306
Impaired drainage of vein of Labbé following venous sinus stenting for idiopathic intracranial hypertension
Purpose: The impact of venous sinus stenting (VSS) on vein of Labbé (VOL) drainage is poorly understood. The purpose of the study is to examine the incidence and potential high risk factors of impaired VOL drainage among idiopathic intracranial hypertension (IIH) patients following VSS.Materials and methods: Institutional review board approved prospective evaluation of all IIH patients who underwent VSS over a 5 year period (January 2012 to December 2017) at Weill Cornell Medical Center constituted the study population. Patient demographics, procedural details (laterality of stenting, balloon angioplasty, number of stents, and stent diameters), morphology of the VOL and changes in the flow in the VOL, type of sinus stenosis, and transverse sinus symmetry were evaluated. We used χ2analysis to evaluate impaired VOL drainage against other variables. Statistical significance was set at 0.05.Results: 70 consecutive patients (67 women, 3 men) with a mean age of 31±9.8 years underwent VSS. Stenosis was extrinsic in 63% (n=44) and intrinsic in 37% (n=26) of patients. Impaired drainage of the VOL was detected in 9/70 (13%) patients. Ipsilateral VOL was recognized as dominant in 20% (n=14), co-dominant in 51% (n=36), and non-dominant in 29% (n=20) of patients. Impaired VOL drainage was significantly associated with ipsilateral VOL dominance (P=0.001) and stent diameter of ≥9 mm (P=0.042). All patients demonstrated widely patent VOL on follow-up contrast enhanced MR venography at 3 months and 24 months.Conclusion: Impaired drainage of the ipsilateral VOL is a potential consequence of VSS with 13% incidence, and has significant association with ipsilateral superficial cortical venous drainage via dominant VOL and stent diameter of ≥9 mm.Clinical trial registration: NCT01407809.